• Vaccine Name: rVSV-EBOV
• Target Pathogen: Ebola virus
• Target Disease: Ebola hemorrhagic fever
• Vaccine Ontology ID: VO_0004660
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• GP from Zaire ebolavirus gene engineering:
  • Type: Recombinant vector construction
  • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Zaire ebolavirus (ZEBOV) (Falzarano et al., 2011).
  • Detailed Gene Information: Click Here.
• GP from Cote d'Ivoire Ebola virus gene engineering:
  • Type: Recombinant vector construction
  • Description: The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a glycoprotein of Côte d’Ivoire ebolavirus (CIEBOV) (Falzarano et al., 2011).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001025
• Preparation: A recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein (Falzarano et al., 2011).
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: Cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) (Falzarano et al., 2011).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The macaques were challenged with Bundibugyo ebolavirus (BEBOV)(Falzarano et al., 2011).
• Efficacy: A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively) (Falzarano et al., 2011).